MOTS-C (10 mg Vial)

MOTS-C Research Reference

MOTS-C is referenced at 200 mcg–1 mg daily in educational research settings. A 10 mg vial prepared with bacteriostatic water provides approximately 3.33 mg/mL. Research references discuss gradual adjustment over roughly 10 weeks. This information is provided for research and educational use only.

MOTS-C is a 16-amino-acid mitochondrial-derived peptide (MDP) that acts as a metabolic regulator, primarily through AMPK activation. Preclinical studies suggest roles related to insulin sensitivity, fat oxidation, exercise capacity, and age-related metabolic pathways. No completed human clinical trials are currently available. This educational reference presents general scientific information aligned with preclinical findings.

Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety information, read MOTS-C Peptide: Benefits, Uses, Research Background.

Educational guide for preparation and daily reference information

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Week	Daily Research (mcg)	Units (mL)
Weeks 1–2	200 mcg (0.2 mg)	6 units (0.06 mL)
Weeks 3–4	400 mcg (0.4 mg)	12 units (0.12 mL)
Weeks 5–6	600 mcg (0.6 mg)	18 units (0.18 mL)
Weeks 7–8	800 mcg (0.8 mg)	24 units (0.24 mL)
Weeks 9–10+	1,000 mcg (1.0 mg)	30 units (0.30 mL)

Frequency: Apply once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) to maintain accurate measurement. Stay at each reference level for approximately 2 weeks before increasing, and monitor for any adverse responses. For <10-unit (≤0.10 mL) applications, consider 30- or 50-unit measurement devices for improved readability.

Preparation Steps

Important: This guide is for educational purposes only and is not medical advice. MOTS-C is an experimental compound for research reference only. Not for human consumption.

Plan based on an 8–12 week daily research schedule with gradual adjustment.

Concise summary of the once-daily research schedule.

Goal: Support metabolic homeostasis, insulin sensitivity, and age-related physical performance based on preclinical evidence.
Schedule: Daily subcutaneous application for 8–12 weeks (extend to 16 weeks if desired).
Reference Range: 200–1,000 mcg daily with gradual adjustment over 10 weeks.
Preparation: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate measurement reference.
Storage: Lyophilized material stored at −20 °C (−4 °F); prepared solution refrigerated at 2–8 °C (35.6–46.4 °F); avoid repeated freeze–thaw cycles.

Suggested daily adjustment approach based on available research references.

Start: 200 mcg daily for 2 weeks.
Adjustment: Increase by ~200 mcg every 2 weeks: 400 mcg (Weeks 3–4), 600 mcg (Weeks 5–6), 800 mcg (Weeks 7–8).
Reference Target: Up to 1,000 mcg (1.0 mg) daily by Weeks 9–10+ if well tolerated.
Frequency: Once per day (subcutaneous).
Cycle Length: 8–12 weeks; optional extension to 16 weeks.
Timing: Any consistent time; rotate application sites.

Proper storage preserves peptide quality and stability.

Lyophilized: Store at −20 °C (−4 °F) or below in dry, dark conditions; include desiccant if available to minimize moisture exposure.
Prepared: Refrigerate at 2–8 °C (35.6–46.4 °F); material may degrade at room temperature. Use within 7 days for best stability.
Aliquoting: Prepare single-use portions and freeze at −20 °C (−4 °F) if needed; avoid repeated freeze–thaw cycles.
Allow containers to reach room temperature before opening to reduce condensation uptake.

Practical considerations for consistency and safety.

Use new sterile measurement devices for each application; dispose of used items in a proper sharps container.
Rotate application areas (abdomen, thighs, upper arms) to reduce local irritation and prevent tissue changes.
Apply slowly; wait a few seconds before removing the needle.
Document daily reference amount, application area, and any observations to maintain consistency.
Discontinue use and consult a medical professional if any concerning symptoms arise.

MOTS-C functions as a metabolic “stress signal” that helps optimize energy usage during nutrient stress or exercise. Its primary mechanism involves AMPK activation through cellular energy pathways, supporting glucose uptake, fatty-acid oxidation, and mitochondrial respiration. MOTS-C may also influence cellular stress responses and antioxidant pathways. Research indicates potential roles related to mitochondrial function, metabolic regulation, and age-associated changes.

Observations from preclinical literature (no human clinical trials completed to date).

Metabolic Health: Improves insulin sensitivity and glucose metabolism in mouse models; prevents diet-induced insulin resistance.
Weight & Fat Reduction: Reduces obesity and visceral fat in obese mice through increased energy expenditure and fat oxidation.
Post-Menopausal Metabolism: Supports metabolic balance in ovariectomized mice and reduces menopause-related fat gain and insulin resistance.
Physical Performance: Enhances exercise capacity and supports age-related physical function in research models.
Organ Protection: Reduces liver fat accumulation, supports cardiac function, and may influence cognitive function in preliminary studies.
Bone & Immunity: Promotes osteoblast activity, influences osteoclast formation, supports immune aging, and protects pancreatic islet cells in autoimmune diabetes models.
Safety: No adverse effects reported in preclinical studies; human tolerability remains unknown. A modified analog (CB4211) showed good tolerability in a Phase 1 trial.

Note: These benefits have been demonstrated only in controlled research settings (mice or cells). Translation to humans requires clinical studies.

Complementary strategies for supporting outcomes based on MOTS-C metabolic mechanisms.

Nutrition: Pair with a balanced, protein-forward diet tailored to energy needs.
Exercise: Combine resistance training and aerobic activity to support metabolic adaptations and AMPK signaling.
Sleep: Prioritize 7–9 hours of quality sleep and stress management to support mitochondrial health and recovery.
Fasting: Consider intermittent fasting or caloric restriction, which may influence MOTS-C related metabolic pathways.

General subcutaneous guidance from clinical best-practice resources.

Site Preparation: Clean the container stopper and skin area with alcohol; allow to dry completely.
Application Angle: Pinch a skinfold; insert the needle at approximately 90° (45° if very lean) into subcutaneous tissue.
Administration: Do not aspirate for subcutaneous applications; apply slowly and steadily over a few seconds.
After Application: Withdraw the needle at the same angle; apply gentle pressure if bleeding occurs (do not rub).
Site Rotation: Rotate areas systematically (abdomen at least 2 inches from navel, outer thighs, back of upper arms) to avoid irritation and tissue changes.
Disposal: Dispose of used devices immediately in a proper sharps container (never reuse).

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. MOTS-C is an experimental compound for research use only. No clinical trials have been completed in humans. Always consult qualified healthcare providers before starting any new therapy.

Cell Metabolism (2015)

— The mitochondrial-derived peptide MOTS-C promotes metabolic homeostasis and reduces obesity and insulin resistance (Lee C, Zeng J, Drew BG, et al.)

Journal of Translational Medicine (2023)

— Mitochondria-derived peptide MOTS-C: effects and mechanisms related to stress, metabolism and aging (Wan W, Zhang L, Lin Y, et al.)

Journal of Molecular Medicine (2019)

— MOTS-C peptide regulates metabolic homeostasis to prevent ovariectomy-induced metabolic dysfunction (Hu Y, Wei W, Zhai Y, et al.)

Nature Communications (2021)

— MOTS-C is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis (Reynolds JC, Lai RW, Woodhead JST, et al.)

Frontiers in Physiology (2023)

— Role of MOTS-C in the regulation of bone metabolism (Yi X, Hu G, Yang Y, et al.)

Cognitive Vitality Reports (2021)

— MOTS-C (Cognitive Vitality Profile) — Alzheimer’s Drug Discovery Foundation (ADDF)

USADA Spirit of Sport (2023)

— What is the MOTS-C peptide? — U.S. Anti-Doping Agency educational article

Experimental & Molecular Medicine (2025)

— Mitochondrial-encoded peptide MOTS-C prevents pancreatic islet cell senescence to delay diabetes (Kong BS, Lee H, Ly S, et al.)

MedlinePlus Medical Encyclopedia (2023)

— Subcutaneous (SQ) application guidance — patient instructions for proper technique